Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model

Wolburg, 2009, Brain endothelial cells and the glio-vascular complex, Cell Tissue Res, 335, 75, 10.1007/s00441-008-0658-9 Omidi, 2008, Characterization and astrocytic modulation of system L transporters in brain microvasculature endothelial cells, Cell Biochem Funct, 26, 381, 10.1002/cbf.1455 de Boer, 2003, The role of drug transporters at the blood-brain barrier, Annu Rev Pharmacol Toxicol, 43, 629, 10.1146/annurev.pharmtox.43.100901.140204 Deeken, 2007, The blood-brain barrier and cancer: transporters, treatment, and Trojan horses, Clin Cancer Res, 13, 1663, 10.1158/1078-0432.CCR-06-2854 Cerletti, 2000, Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system, J Drug Target, 8, 435, 10.3109/10611860008997919 Markoutsa, 2011, Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line, Eur J Pharm Biopharm, 77, 265, 10.1016/j.ejpb.2010.11.015 Dehouck, 1994, Upregulation of the low-density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes, J Cell Biol, 126, 465, 10.1083/jcb.126.2.465 Dehouck, 1997, A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier, J Cell Biol, 138, 877, 10.1083/jcb.138.4.877 Mims, 1994, A nonexchangeable apolipoprotein E peptide that mediates binding to the low-density lipoprotein receptor, J Biol Chem, 269, 20539, 10.1016/S0021-9258(17)32027-6 Datta, 2000, The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts, Biochemistry, 39, 213, 10.1021/bi991209w Dyer, 1995, Structural features of synthetic peptides of apolipoprotein E that bind the LDL receptor, J Lipid Res, 36, 80, 10.1016/S0022-2275(20)39756-X Wang, 1997, Identification of a neuronal endocytic pathway activated by an apolipoprotein E (apoE) receptor binding peptide, Brain Res, 778, 6, 10.1016/S0006-8993(97)00877-9 Sauer, 2005, An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells, Biochemistry, 44, 2021, 10.1021/bi048080x Datta, 2001, Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo, J Lipid Res, 42, 959, 10.1016/S0022-2275(20)31620-5 Brooks, 2005, Tat peptide-mediated cellular delivery: back to basics, Adv Drug Deliv Rev, 57, 559, 10.1016/j.addr.2004.12.001 Schwarze, 1999, In vivo protein transduction: delivery of a biologically active protein into the mouse, Science, 285, 1569, 10.1126/science.285.5433.1569 Eguchi, 2001, Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells, J Biol Chem, 276, 26204, 10.1074/jbc.M010625200 Tian, 2010, Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats, Eur J Pharm Sci, 41, 232, 10.1016/j.ejps.2010.06.008 Begley, 1996, Functional expression of P-glycoprotein in an immortalised cell line of rat brain endothelial cells, RBE4, J Neurochem, 67, 988, 10.1046/j.1471-4159.1996.67030988.x Roux, 2005, Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions, Cell Mol Neurobiol, 25, 41, 10.1007/s10571-004-1376-9 Zona C, La Ferla B. Synthesis of labeled curcumin derivatives as tools for in vitro blood brain barrier trafficking studies. J Labelled Comp Radiopharm. In press. Gobbi, 2010, Lipid-based nanoparticles with high binding affinity for amyloid-beta-1-42 peptide, Biomaterials, 31, 6519, 10.1016/j.biomaterials.2010.04.044 Bartlett, 1959, Phosphorus assay in column chromatography, J Biol Chem, 234, 466, 10.1016/S0021-9258(18)70226-3 Palestini, 2002, Developmental changes in the protein composition of sphingolipid- and cholesterol-enriched membrane domains of rat cerebellar granule cells, J Neurosci Res, 67, 729, 10.1002/jnr.10170 Roux, 1994, Regulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells, J Cell Physiol, 159, 101, 10.1002/jcp.1041590114 Denizot, 1986, Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability, J Immunol Methods, 89, 271, 10.1016/0022-1759(86)90368-6 Pardridge, 1990, Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier, J Pharmacol Exp Ther, 253, 884 Bickel, 2005, How to measure drug transport across the blood-brain barrier, J Am Soc Exp Neurother, 2, 15 Deli, 2005, Permeability studies on in vitro blood-brain barrier models: physiology, pathology and pharmacology, Cell Mol Neurobiol, 25, 59, 10.1007/s10571-004-1377-8 Cortesi, 1996, Effect of cationic liposome composition on in vitro cytotoxicity and protective effect on carried DNA, Int J Pharm, 139, 69, 10.1016/0378-5173(96)04574-7 Smistad, 2007, Multivariate toxicity screening of liposomal formulations on a human buccal cell line, Int J Pharm, 330, 14, 10.1016/j.ijpharm.2006.08.044 Mayhev, 1987, Toxicity of non-drug-containing liposomes for cultured human cells, Exp Cell Res, 171, 195, 10.1016/0014-4827(87)90262-X Boehlke, 2006, Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drug, Expert Opin Biol Ther, 6, 409, 10.1517/14712598.6.4.409 Thomas, 2006, Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia, Cancer, 106, 120, 10.1002/cncr.21595 Adams, 1977, Liposome toxicity in the mouse central nervous system, J Neurol Sci, 31, 173, 10.1016/0022-510X(77)90104-6 Pardridge, 2000, Drug and gene targeting to the brain with Trojan horses, Nature Rev Drug Discov, 1, 131, 10.1038/nrd725 Reichel, 2002, Evaluation of the RBE4 cell line to explore carrier-mediated drug delivery to the CNS via the L-system amino acid transporter at the blood-brain barrier, J Drug Target, 10, 277, 10.1080/10611860290031930 Re, 2010, Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease, Curr Med Chem, 17, 2990, 10.2174/092986710791959729 Zhang, 2010, Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein, J Biol Chem, 285, 28472, 10.1074/jbc.M110.133520 Mourtas, 2011, Curcumin-decorated NL with very high affinity for amyloid-β1-42 peptide, Biomaterials, 32, 1635, 10.1016/j.biomaterials.2010.10.027 Sharma, 2005, Curcumin: the story so far, Eur J Cancer, 41, 1955, 10.1016/j.ejca.2005.05.009 Narlawar, 2008, Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease?, Chem Med Chem, 3, 165, 10.1002/cmdc.200700218 Ono, 2004, Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro, J Neurosci Res, 75, 742, 10.1002/jnr.20025 Garcia-Alloza, 2007, Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model, J Neurochem, 102, 1095, 10.1111/j.1471-4159.2007.04613.x Khumsupan, 1808, Apolipoprotein E LDL receptor-binding domain-containing high-density lipoprotein: a nanovehicle to transport curcumin, an antioxidant and anti-amyloid bioflavonoid, Biochim Biophys Acta., 2011, 352 Ray, 2011, Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc®) in the neuronal cell culture and animal model: implications for Alzheimer's disease, J Alzheimers Dis, 23, 61, 10.3233/JAD-2010-101374